BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
To create leading company developing medicines targeting metalloenzymes
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Positive opinions based on significant survival benefit
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The product is backed by required scientific proof and comparative bioequivalence studies
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
LG Chem will receive totaling up to $95.5 million for the China rights
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
